TLP
MDGL icon

Tri Locum Partners’s Madrigal Pharmaceuticals MDGL Stock Holding History

Tri Locum Partners’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$54.1M Buy
103,288
+17,265
+20% +$8.25M 7.59% 7
2025
Q4 		$50.1M Buy
86,023
+18,317
+27% +$9.36M 6.5% 6
2025
Q3 		$31.1M Sell
67,706
-30,059
-31% -$11.2M 7.14% 8
2025
Q2 		$29.6M Buy
97,765
+59,896
+158% +$17.8M 8.98% 2
2025
Q1 		$12.5M Sell
37,869
-9,603
-20% -$3.16M 6.44% 6
2024
Q4 		$14.6M Buy
47,472
+4,185
+10% +$1.18M 3.03% 14
2024
Q3 		$9.19M Sell
43,287
-22,065
-34% -$5.64M 2.2% 16
2024
Q2 		$18.3M Buy
65,352
+11,997
+22% +$2.86M 4.63% 10
2024
Q1 		$14.2M Buy
53,355
+27,831
+109% +$6.56M 4.94% 9
2023
Q4 		$5.91M Sell
25,524
-8,237
-24% -$1.44M 2.7% 15
2023
Q3 		$4.93M Buy
33,761
+7,751
+30% +$1.46M 1.58% 24
2023
Q2 		$6.01M Buy
26,010
+12,165
+88% +$3.29M 2.23% 18
2023
Q1 		$3.35M Sell
13,845
-12,541
-48% -$3.42M 1.02% 29
2022
Q4 		$7.66M Buy
+26,386
New +$2.58M 3.1% 12

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Tri Locum Partners's MDGL Position: Q1 2026 in Review

Tri Locum Partners increased its Madrigal Pharmaceuticals (MDGL) stake by 20% in Q1 2026, buying an estimated $8.25M and bringing the position to 103,288 shares worth $54.1M. The position accounts for 7.59% of the portfolio, ranked #7.

Tri Locum Partners first reported a position in MDGL in Q4 2022 and has held it in 14 quarters since. 378 funds tracked by Wall St. Rank hold MDGL as of Q1 2026.

  • Tri Locum Partners held 103,288 shares of Madrigal Pharmaceuticals worth $54.1M as of Q1 2026.
  • Tri Locum Partners bought 17,265 Madrigal Pharmaceuticals shares in Q1 2026, an estimated $8.25M.
  • Madrigal Pharmaceuticals made up 7.59% of Tri Locum Partners's portfolio in Q1 2026, its #7 holding.
  • Tri Locum Partners first reported a position in Madrigal Pharmaceuticals in Q4 2022 and has held it in 14 quarters since.
  • 378 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2026.

Based on Tri Locum Partners's 13F filing for Q1 2026, filed 18 May 2026.